Compound class:
Synthetic organic
Comment: Example 4 is a highly potent, small-molecule inhibitor of the PD-1/PD-L1 interaction that is claimed in patent WO2017202275A1 [1].
|
|
Immunopharmacology Comments |
Example 4 was developed to disrupt the inhibitory immune checkpoint interaction between PD-1 and PD-L1, as an alternative to antibody-based checkpoint inhibitors. Checkpoint inhibitors have important immuno-oncology therapeutic use, and potential for application in autoimmune diseases. |